biostudies-literatureTrujillo-Rodriguez MInstituto de Salud Carlos IIIAndalusian Network for the Design and Translation of Advanced TherapiesRed de Investigación en SIDAAndalusian Regional Ministry of Health and Families534-541https://www.ebi.ac.uk/biostudies/studies/S-EPMC7980217biostudies-literatureUnknown10(4)Between 15% and 30% of HIV-infected subjects fail to increase their CD4⁺ T-cell counts despite continuous viral suppression (immunological nonresponders [INRs]). These subjects have a higher morbidity and mortality rate, but there are no effective treatments to reverse this situation so far. This study used data from an interrupted phase I/II clinical trial to evaluate safety and immune recovery after INRs were given four infusions, at baseline and at weeks 4, 8, and 20, with human allogeneic mesenchymal stromal cells from adipose tissue (Ad-MSCs). Based on the study design, the first 5 out of 15 INRs recruited received unblinded Ad-MSC infusions. They had a median CD4⁺ nadir count of 16/μL (range, 2-180) and CD4⁺ count of 253 cells per microliter (171-412)Stem cells translational medicineMesenchymal stromal cells in human immunodeficiency virus-infected patients with discordant immune response: Early results of a phase I/II clinical trial.PMC7980217PI15/01041RD16/0025/0020-ISCIII-FEDER201600073585-traMata RMartinez-Atienza JRivas-Jeremias IRuiz-Garcia AArias-Santiago SAlvarez-Rios AIGutierrez-Valencia AEspinosa-Ibanez ORuiz-Mateos EFernandez-Lopez OTrujillo-Rodriguez MViciana PLopez-Cortes LFfalseMesenchymal stromal cells in human immunodeficiency virus-infected patients with discordant immune response: Early results of a phase I/II clinical trial.Between 15% and 30% of HIV-infected subjects fail to increase their CD4⁺ T-cell counts despite continuous viral suppression (immunological nonresponders [INRs]). These subjects have a higher morbidity and mortality rate, but there are no effective treatments to reverse this situation so far. This study used data from an interrupted phase I/II clinical trial to evaluate safety and immune recovery after INRs were given four infusions, at baseline and at weeks 4, 8, and 20, with human allogeneic mesenchymal stromal cells from adipose tissue (Ad-MSCs). Based on the study design, the first 5 out of 15 INRs recruited received unblinded Ad-MSC infusions. They had a median CD4⁺ nadir count of 16/μL (range, 2-180) and CD4⁺ count of 253 cells per microliter (171-412)2021-01-01T00:00:00Z2021 Apr2026-05-07T14:54:37.33Z2025-04-05T19:14:11.015ZS-EPMC79802173326451510.1002/sctm.20-0213